Startups

Senior Director, Safety Scientist

Parabilis Medicines · Remote · Remote

← All jobs
About Parabilis Medicines

Backed by General Catalyst and GV.

About the role

Parabilis Medicines is seeking an experienced and strategic Senior Director, Safety Scientist to provide scientific leadership for safety surveillance and risk management across our clinical development portfolio.

What they're looking for

  • Advanced degree in Life Sciences, Pharmacy, Nursing, Medicine (PharmD, Ph.D.) required. MDs will also be considered
  • 12+ years of experience in pharmacovigilance, drug safety, or safety science within the biotechnology or pharmaceutical industry, including significant experience supporting clinical stage development programs
  • Demonstrated expertise in safety surveillance, signal detection and management, benefit-risk assessment, and safety risk management across multiple phases of clinical development
  • Experience supporting regulatory interactions and preparing responses to global health authorities related to safety topics
  • Strong working knowledge of global pharmacovigilance regulations and guidance, including FDA, EMA, and ICH requirements
  • Experience utilizing safety databases, MedDRA coding, Standardized MedDRA Queries (SMQs), and safety data visualization and analytics tools (e.g., Spotfire)
More about this role

About Parabilis Medicines

Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP) and a range of other solid tumor indications. Beyond zolucatetide, Parabilis is advancing additional Helicon-based programs focused on other challenging targets where we believe our medicines could have life-altering impact. For more information, visit www.parabilismed.com or follow us on LinkedIn .

Parabilis Medicines is seeking an experienced and strategic Senior Director,...

Read the full posting on Parabilis Medicines's site ↗

Development

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.